ArticleNature communications2018
Sensitive and frequent identification of high avidity neo-epitope specific CD8
2 registry-linked trialsOpen access · goldAbstract read
In one paragraph
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 111 papers.
0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed
8.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Peptide-based Immunization for Colon- and Pancreas-carcinoma (PICOP-GLOBAL): An International, Multicenter Protocol
Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Advanced High-grade Serous Ovarian Cancer in Blood, Ascites, Peritoneal Biopsy
Who cites it
111 citing papers in PubMed, 162 citations in OpenAlex.
- Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial.Nature communications · 2025Trial
- Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.Journal for immunotherapy of cancer · 2019Trial
- Rethinking ovarian cancer III: the past decade and future directions.Nature reviews. Cancer · 2026Review
- Advances in predicting T cell epitope recognition for cancer immunotherapy.Nature cancer · 2026Review
- Terminal T-cell exhaustion predicts tumor control independent of immunotherapy in ovarian cancer.NPJ precision oncology · 2026Article
- Neoantigen-based cancer vaccines: a mechanistic and clinical review of personalised melanoma immunotherapy.Frontiers in immunology · 2026Review
- Facts and Hopes for Neoantigen-Enriched TIL.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Review
- Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic.Journal for immunotherapy of cancer · 2025Review
- Highly efficient gene knockout in tumor-infiltrating lymphocytes by adenine base editing.Molecular therapy. Oncology · 2025Article
- HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancer.Journal for immunotherapy of cancer · 2025Article
- Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy.Cancer cell · 2025Article
- Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancer.Science advances · 2025Article
- Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity.Cell · 2025Article
- Integration of proteomics profiling data to facilitate discovery of cancer neoantigens: a survey.Briefings in bioinformatics · 2025Review
- Visual analysis of ovarian cancer immunotherapy: a bibliometric analysis from 2010 to 2025.Frontiers in medicine · 2025Review
- Detection of spontaneous anti-neoepitope T-cell responses in non-metastatic bladder cancer patients.Frontiers in immunology · 2025Article
- Immune checkpoints and ncRNAs: pioneering immunotherapy approaches for hematological malignancies.Cancer cell international · 2024Review
- Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach.Nature reviews. Clinical oncology · 2024Review
- Predicting Antigen-Specificities of Orphan T Cell Receptors from Cancer Patients with TCRpcDist.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Focusing on CD8Journal of experimental & clinical cancer research : CR · 2024Review
51 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 5 institutions in 2 countries.
Sara BobisseDepartment of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, CH-1066, Switzerland.
Raphael GenoletDepartment of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, CH-1066, Switzerland.
Annalisa RobertiOvarian Cancer Research Center, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Janos L TanyiOvarian Cancer Research Center, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Julien RacleDepartment of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, CH-1066, Switzerland.ORCID http://orcid.org/0000-0002-0100-0323
Brian J StevensonSwiss Institute of Bioinformatics, Lausanne, CH-1015, Switzerland.
Christian IseliSwiss Institute of Bioinformatics, Lausanne, CH-1015, Switzerland.
Alexandra MichelDepartment of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, CH-1066, Switzerland.
Marie-Aude Le BitouxDepartment of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, CH-1066, Switzerland.
Philippe GuillaumeDepartment of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, CH-1066, Switzerland.
Julien SchmidtDepartment of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, CH-1066, Switzerland.
Valentina BianchiDepartment of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, CH-1066, Switzerland.
Denarda DangajDepartment of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, CH-1066, Switzerland.
Craig FenwickDepartment of Medicine, Division of Immunology and Allergy, Lausanne University Hospital, Lausanne, CH-1066, Switzerland.
Laurent DerréUrology Research Unit, Lausanne University Hospital, Lausanne, CH-1011, Switzerland.ORCID http://orcid.org/0000-0002-3403-161X
Ioannis XenariosSwiss Institute of Bioinformatics, Lausanne, CH-1015, Switzerland.
Olivier MichielinDepartment of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, CH-1066, Switzerland.
Pedro RomeroDepartment of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, CH-1066, Switzerland.
Dimitri S MonosDepartment of Pathology and Laboratory Medicine, Immunogenetics Laboratory, The Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
Vincent ZoeteDepartment of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, CH-1066, Switzerland.
David GfellerDepartment of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, CH-1066, Switzerland.
Lana E KandalaftDepartment of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, CH-1066, Switzerland.
George CoukosDepartment of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, CH-1066, Switzerland. george.coukos@chuv.ch.
Alexandre HarariDepartment of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, CH-1066, Switzerland. alexandre.harari@chuv.ch.ORCID http://orcid.org/0000-0002-1055-2090
Ludwig Cancer Research · CHSIB Swiss Institute of Bioinformatics · CHCancer Research Center · USUniversity of Lausanne · CHChildren's Hospital of Philadelphia · US
Funding
Therapeutic Micro RNA Strategies for Ovarian CancerP50CA083638 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI GODWIN, ANDREW K., GOLEMIS, ERICA A. · 1999 to 2013
$33.6MNCI NIH HHS P50 CA083638
Abstract
Immunotherapy directed against private tumor neo-antigens derived from non-synonymous somatic mutations is a promising strategy of personalized cancer immunotherapy. However, feasibility in low mutational load tumor types remains unknown. Comprehensive and deep analysis of circulating and tumor-infiltrating lymphocytes (TILs) for neo-epitope specific CD8
Indexed as
Antigens, NeoplasmCD8-Positive T-LymphocytesEpitopes, T-LymphocyteFemaleHumansImmunotherapyLymphocytes, Tumor-InfiltratingOvarian NeoplasmsReceptors, Antigen, T-CellAntigens, NeoplasmEpitopes, T-LymphocyteReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT03871790ClinicalTrials.gov
NCT03922776ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.